1. Jouven X, Empana J-P, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death N Engl J Med 2005;352:1951-1958.


Palatini P, Julius S. Elevated heart rate: a major risk fac­tor for cardiovascular disease Clin Exp Hypertens 2004;26:637- 644.

3. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for anti­hypertensive drug therapy Drugs 2006;66:133-144.

4. Kovar D, Cannon CP, Bentley JH, Charlesworth A, Rogers WJ. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol 2004;27:80-86.

5. Diaz A, Bourassa MG, Guertin M-C, Tardif J-C. Long­term prognostic value of resting heart rate in patients with sus­pected or proven coronary artery disease Eur Heart J 2005;26:967-974.

6. Palatini P, Thijs L, Staessen JA, et al. Predictive power of clinical and ambulatory heart rate for mortality in elderly subjects with systolic hypertension Arch Intern Med 2002;162:2313-2321.

7. Bonnemeier H, Wiegand UKH, Brandes A, et al. Cir­cadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability J Cardiovasc Electrophysiol 2003;14:791-799.

8. Eagle KA, Lim MJ, Dabbous OH, et al. A validated pre­diction model for all forms of acute coronary syndrome: estimat­ing the risk of 6-month postdischarge death in an international registry JAMA 2004;291:2727-2733.

В.А. Снежицкий

» »

9. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multi- ple-risk-factor assessment equations: GISSI-Prevenzione mortal­ity risk chart Eur Heart J 2001;22:2085-2103.

10. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentationAn In­travenous nPA for Treatment of Infarcting Myocardium Early II Trial substudy.

Circulation 2000;102:2031-2037.

11. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy Lancet 2001;358:1571-1575.

12. Wiviott SD, Morrow DA, Frederick PD, et al. Perform­ance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple in­dex that predicts mortality in ST-segment elevation myocardial infarction J Am Coll Cardiol 2004;44:783-789.

13. Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. A new method for CHD prediction and pre­vention based on regional risk scores and randomized clinical tri­als: PRECARD and the Copenhagen Risk Score J Cardiovasc Risk 2001;8:291-297.

14. Conroy RM, Pyorala K, Fitzferald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 2003;24:987-1003.

15. Janssen I, Katzmarzyk PT, Church TS, Blair SN. The Cooper Clinic mortality risk index clinical score sheet for men Am J Prev Med 2005;29:194-203.

16. Hooper L, Thompson RL, Harrison EA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review BMJ 2006;332:752-760.

17. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial in­farction intervention trials Am J Cardiol 1986;57:43F-49F.

18. Gundersen T, Grottum P, Pedersen T, Kjekshus JK. Ef­fect of timolol on mortality and reinfarction after acute myocar-

1. Частота сердечных сокращений и риск сердечно-сосудистых заболеваний Ф Ф

dial infarction: prognostic importance of heart rate at rest Am J

Cardiol 1986;58:20-24.

19. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Sec­ondary prevention after high-risk acute myocardial infarction with low-dose acebutolol Am J Cardiol 1990;66:251-260.

20. Task Force of the European Society of Cardiology Man­agement of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology Eur Heart J 1997;18:394-413.

21. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardi­ology/American Heart Association Task Force on Practice Guide­lines (Committee on the Management of Patients with Chronic Stable Angina). Available at:

http://www.acc.org/qualityandscience/clinical/guidelines/stable/u pdate_index.htm. Accessed May 3, 2006.

22. van der Vring JA, Daniels MC, Holwerda NJ, et al. Combination of calcium channel blockers and B-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers Br J Clin Pharmacol 1999;47:493-498.

23. Kjekshus J, Gullestad L. Heart rate as a therapeutic tar­get in heart failure Eur Heart J Suppl 1999;1(Suppl H):H64-H69.

24. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS) Circu­lation 1997;96:2197-2205.

25. Lechat P, Hulot J-S, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial Circulation 2001;103:1428-1433.

26. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial Eur Heart J 2005;26:2259-2268.

27. Gullestad L, Wikstrand J, Deedwania P, et al. What rest­ing heart rate should one aim for when treating patients with heart

В.А. Снежицкий

» »

failure with a beta-blocker?Experiences from the Metoprolol Con­trolled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005;45:252-259.

28. Orso, F. Heart rate in coronary syndromes and heart failure / F.

Orso, S. Baldasseroni, A.P. Maggioni // Prog. Cardio- vasc. Dis. - 2009. - Vol. 52, № 1 - P. 38-45.

29. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT) / K. Swedberg [et al.] // Eur. J. Heart Fail. - 2010. - Vol 12, № 1. - P. 75-81.

30. Kaplan JR, Manuck SB, Clarkson TB. The influence of heart rate on coronary artery atherosclerosis J Cardiovasc Phar­macol 1987;10(Suppl 2):S100-S102.

31. Beere PA, Glagov S, Zarins CK. Experimental athero­sclerosis at the carotid bifurcation of the cynomolgus monkeyLo- calization, compensatory enlargement, and the sparing effect of lowered heart rate. Arterioscler Thromb 1992;12:1245-1253.

32. Huikuri HV, Jokinen V, Syvanne M, et al. Heart rate variability and progression of coronary atherosclerosis Arterio- scler Thromb Vasc Biol 1999;19:1979-1985.

33. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque dis­ruption Circulation 2001;104:1477-1482.

34. Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo J Hypertens 1996;14:897-901.

35. Sa Cunha R, Pannier B, Benetos A, et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects J Hypertens 1997;15:1423-1430.

36. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force Arte- rioscler Thromb Vasc Biol 1998;18:677-685.

37. Tanaka N, Nozawa T, Yasumura Y, Futaki S, Hiramori K, Suga H. Heart-rate-proportional oxygen consumption for con­stant cardiac work in dog heart Jpn J Physiol 1990;40:503-521.

1. Частота сердечных сокращений и риск сердечно-сосудистых заболеваний Ф Ф

38. Sambuceti G, Marzilli M, Marraccini P, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease Circu­lation 1997;95:2652-2659.

39. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with coronary artery disease J Am Coll Cardiol 1992;20:1092-1098.

40. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activityCir- cadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993;88:92-100.

41. Pratt CM, McMahon RP, Goldstein S, et al. Comparison of subgroups assigned to medical regimens used to suppress car­diac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study) Am J Cardiol 1996;77:1302-1309.

42. Guth BD, Heusch G, Seitelberger R, Ross J. Mechanism of beneficial effect of B-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs Circ Res 1987 ;60:738- 746.

43. Simonsen S, Ihlen H, Kjekshus JK. Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocar­dium Acta Med Scand 1983;213:393-398.

44. Reynolds RD, Calzadilla SV, Lee RV. Spontaneous heart rate, propranolol, and ischaemia-induced ventricular fibrilla­tion in the dog Cardiovasc Res 1978;12:653-658.

45. Bolli R, Fisher DJ, Entman ML. Factors that determine the occurrence of arrhythmias during acute myocardial infarction Am Heart J 1986;111:261-270.

46. Aupetit JF, Frassati D, Bui-Xuan B, Freysz M, Faucon G, Timour Q. Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: de­pendence on heart rate and ischaemia duration Cardiovasc Res 1998;37:646-655.

В.А. Снежицкий

» »

47. Вариабельность ритма сердца: применение в кар­диологии : монография / В.А. Снежицкий [и др.] ; под общ. ред. В.А. Снежицкого. - Гродно : ГрГМУ, 2010. - 212 с.

48. La Rovere MT, Pinna GN, Hohnloser SH, et al. Barore- flex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials Circulation 2001;103:2072-2077.

49. Abildstrom SZ, Jensen BT, Agner E, et al. Heart rate versus heart rate variability in risk prediction after myocardial in­farction J Cardiovasc Electrophysiol 2003;14:168-173.

50. Ghuran A, Reid F, La Rovere MT, et al. Heart rate tur­bulence-based predictors of fatal and nonfatal cardiac arrest (the Autonomic Tone and Reflexes After Myocardial Infarction substudy) Am J Cardiol 2002;89:184-190.

51. Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study Lancet 2006;367:1674-1681.

52. Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in pa­tients after a recent myocardial infarction: a randomized, placebo- controlled trial of azimilide using heart rate variability for risk stratification Circulation 2004;109:990-996.

53. Снежицкий В.А. Дисфункция синусового узла : мо­нография. - Гродно, УО «ГрГМУ», 2006. - 220 с.

54. Оценка циркадианного ритма частоты сердечных со­кращений при пароксизмальной фибрилляции предсердий / В.А. Снежицкий, Е.С. Пелеса, Н.В. Шпак, Е.А. Снежицкая // Клиническая медицина. - 2008. - № 8. - С. 29-32.

55. Ramaswamy K. Beta blockers improve outcome in pa­tients with heart failure and atrial fibrillation: U.S. carvedilol study Card Electrophysiol Rev 2003;7:229-232.

56. Kowey PR. A review of carvedilol arrhythmia data in clinical trials J Cardiovasc Pharmacol Ther 2005;10(Suppl 1):S59-S68.

57. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrilla­tion N Engl J Med 2002;347:1825-1833.

58. Van Gelder IC, Wyse DG, Chandler ML, et al. Does in­tensity of rate-control influence outcome in atrial fibrillation?An

1. Частота сердечных сокращений и риск сердечно-сосудистых заболеваний Ф Ф

analysis of pooled data from the RACE and AFFIRM studies. Eu-

ropace 2006;8:935-942.

59. Nagatsu M, Spinale FG, Koide M, et al. Bradycardia and the role of В-blockade in the amelioration of left ventricular dys­function Circulation 2000;101:653-659.

60. Mulder P, Barbier S, Chagroui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor iv- abradine improves left ventricular function and intrinsic myocar­dial structure in congestive heart failure Circulation 2004;109:1674-1679.

61. Yamakawa H, Takeuchi M, Takaoka H, Hata K, Mori M, Yokayama M. Negative chronotropic effect of В-blockade therapy reduces myocardial oxygen expenditure for nonmechani­cal work Circulation 1996;94:340-345.

62. Thackray SDR, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with В-blockers Am Heart J 2006;152:713e9-13.

63. Jurca R, Jackson AS, Lamonte MJ, et al. Assessing car­diorespiratory fitness without performing exercise testing Am J Prev Med 2005;29:185-193.

64. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing N Engl J Med 2002;346:793-801.

65. della Valle E, Stranges S, Trevisan M, Strazzullo P, Siani A, Farinaro E. Self-rated measures of physical activity and cardiovascular risk in a sample of Southern Italian male workers: the Olivetti heart study Nutr Metab Cardiovasc Dis 2004; 14:143­149.

66. Black A, Murray LJ, Cardwell C, Davey Smith G, McCarron P. Secular trends in heart rate in young adults, 1949 to 2004: analyses of cross-sectional studies Heart 2006;92:468-473.

67. Palatini P, Julius S. The physiological determinants and risk correlations of elevated heart rate Am J Hypertens 1999;12:3S-8S.

68. Inoue T, Oshiro S, Iseki K, et al. High heart rate relates to clustering of cardiovascular risk factors in a screened cohort Jpn Circ J 2001;65:969-973.

В.А. Снежицкий

» »

69. Rochon PA, Anderson GA, Tu JV, et al. Use of В- blocker therapy in older patients after acute myocardial infarction in Ontario Can Med Assoc J 1999;161:1403-1408.

70. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence Am Heart J 2003;145:438-444.

71. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo- controlled trial Circulation 2003;107:817-823.

72. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Ef­ficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina Eur Heart J 2005;26:2529-2536.

73. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations Hypertension 1997;30:1267-1273.

74. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30- day mortality in the era of reperfusion for acute myocardial in­farction: results from and international trial of 41,021 patients Circulation 1995;91:1659-1668.

75. Nakagawa M, Iwao T, Ishida S, Yonemochi H, Fujino T, Saikawa T. Circadian rhythm of the signal averaged electrocar­diogram and its relation to heart rate variability in healthy sub­jects Heart 1998;79:493-496.

76. Kristal-Boneh E, Harari G, Weinstein Y, Green MS. Factors affecting differences in supine, sitting, and standing heart rate: the Israeli CORDIS study Aviat Space Environ Med 1995;66:775-779.

77. Palatini P, Benetos A, Grassi G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension consensus meet­ing J Hypertens 2006;24:603-610.

78. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other

1. Частота сердечных сокращений и риск сердечно-сосудистых заболеваний Ф Ф

Societies on Cardiovascular Disease Prevention in Clinical Prac­tice Eur J Cardiovasc Prev Rehabil 2003;10(Suppl 1):S1-S78.

79. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update Circulation



<< | >>
Источник: В.А. Снежицкий. ХРОНОТРОПНАЯ ФУНКЦИЯ СЕРДЦА. 2011

Еще по теме Литература::

  1. § 5Литература по жилищному праву
  2. Литература как фантастика: письмо утопии
  3. Словесность классическая и массовая: литература как идеология и литература как цивилизация
  5. Проблемы периодизации русской литературы XIX века.
  6. Библиографические источники по русской литературе XIX в.
  7. Фольклор и его основные формы. Литература православных славян в XI–XVI вв. Современные славянские литературы
  8. Современная литература глазами психиатра
  9. Литература в 1840 году5
  12. Литература
  13. Литература
  14. Литература
  15. Литература